The estimated Net Worth of James V Caruso is at least $1.2 million dollars as of 4 March 2021. Mr. Caruso owns over 5,100 units of Cellectar Biosciences Inc stock worth over $180,578 and over the last 9 years he sold CLRB stock worth over $81,600. In addition, he makes $934,460 as President, Chief Executive Officer et Director at Cellectar Biosciences Inc.
Sign up
Mr. Caruso CLRB stock SEC Form 4 insiders trading
James has made over 11 trades of the Cellectar Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 5,100 units of CLRB stock worth $8,670 on 4 March 2021.
The largest trade he's ever made was buying 46,948 units of Cellectar Biosciences Inc stock on 20 April 2016 worth over $99,530. On average, James trades about 8,492 units every 88 days since 2015. As of 4 March 2021 he still owns at least 86,401 units of Cellectar Biosciences Inc stock.
You can see the complete history of Mr. Caruso stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Caruso biography
James V. Caruso serves as President, Chief Executive Officer, Director of the Company. Mr. Caruso was appointed our President and Chief Executive Officer and a director in June 2015. He came to Cellectar from Hip Innovation Technology, a medical device company where he was a founder and served as Executive Vice President and Chief Operating Officer from August 2010 to June 2015, and he currently serves on their board. Prior to his time at Hip Innovation Technology, he was Executive Vice President and Chief Commercial Officer of Allos Therapeutics, Inc., an oncology company acquired by Spectrum Pharmaceuticals, from June 2006 to August 2010. He was also Senior Vice President, Sales and Marketing, from June 2002 to May 2005, at Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation. In addition, Mr. Caruso has held key positions at several well-known pharmaceutical companies, including Novartis, where he was Vice President of Neuroscience Specialty Sales, BASF Pharmaceuticals-Knoll, where he was Vice President, Sales, and Bristol-Myers Squibb Company in several senior roles. Mr. Caruso earned a Bachelor of Science degree in Finance from the University of Nevada. Mr. Caruso’s extensive experience in the biotechnology industry and his recent experience as our Chief Executive Officer make him a highly qualified member of our Board of Directors.
What is the salary of James Caruso?
As the President, Chief Executive Officer et Director of Cellectar Biosciences Inc, the total compensation of James Caruso at Cellectar Biosciences Inc is $934,460. There are no executives at Cellectar Biosciences Inc getting paid more.
How old is James Caruso?
James Caruso is 61, he's been the President, Chief Executive Officer et Director of Cellectar Biosciences Inc since 2015. There are 4 older and 7 younger executives at Cellectar Biosciences Inc. The oldest executive at Cellectar Biosciences Inc is Frederick Driscoll, 69, who is the Independent Director.
What's James Caruso's mailing address?
James's mailing address filed with the SEC is C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932.
Insiders trading at Cellectar Biosciences Inc
Over the last 10 years, insiders at Cellectar Biosciences Inc have traded over $1,263,511 worth of Cellectar Biosciences Inc stock and bought 1,917,793 units worth $3,966,598 . The most active insiders traders include Austin W & Greenhouse David..., Investment Company, Inc. Awm et John Neis. On average, Cellectar Biosciences Inc executives and independent directors trade stock every 50 days with the average trade being worth of $126,821. The most recent stock trade was executed by Douglas J Swirsky on 14 September 2021, trading 25,000 units of CLRB stock currently worth $26,000.
What does Cellectar Biosciences Inc do?
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
What does Cellectar Biosciences Inc's logo look like?
Complete history of Mr. Caruso stock trades at Cellectar Biosciences Inc
Cellectar Biosciences Inc executives and stock owners
Cellectar Biosciences Inc executives and other stock owners filed with the SEC include:
-
James Caruso,
President, Chief Executive Officer, Director -
James V. Caruso,
Pres, CEO & Director -
Jarrod Longcor,
Chief Business Officer -
Jarrod Longcor,
Chief Operating Officer -
John Friend,
Vice President, Chief Medical Officer -
Dov Elefant,
Chief Financial Officer, Vice President -
Douglas Swirsky,
Independent Chairman of the Board -
John Neis,
Independent Director -
Stefan Loren,
Independent Director -
Stephen Hill,
Independent Director -
Frederick Driscoll,
Independent Director -
Gregory J. Lynch Esq.,
Sec. -
Dr. Laurence Reilly L.L.M., LL.M, M.D., MBChB,
Interim Chief Medical Officer -
Chad J. Kolean CPA, CPA,
Chief Financial Officer -
Richard Hertzberg,
-
Brian M Posner,
Chief Financial Officer -
Igor D Grachev,
Chief Medical Officer -
Jamey P Weichert,
Chief Scientific Officer -
Paul L Berns,
Director -
Investment Company, Inc. Awm,
10% owner -
John Patrick Genn,
VP of Business Development -
Cameron Szakacs,
VP of Clinical Development -
Simon Pedder,
President and CEO -
Austin W & Greenhouse David...,
10% owner -
Asher Chanan Khan,
Director -
Chad J Kolean,
Chief Financial Officer -
Darrell Shane Lea,
Chief Commercial Officer -
Andrei Shustov,
Senior Vice President, Medical